Key Takeaways on Recent Advances in SCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Anne Chiang, MD, PhD

Key Takeaways

Tarlatamab represents a significant advancement in SCLC treatment, offering new hope beyond first-line therapies.
Clinical trials are investigating novel immunotherapies and targeted treatments, showing promise for SCLC management.
Future SCLC management will likely focus on personalized treatment approaches, integrating novel therapies for improved outcomes.

Panelists discuss how the landscape of small cell lung cancer (SCLC) treatment is rapidly evolving, highlighting key advances in immunotherapy, targeted treatments like tarlatamab, and ongoing research efforts, while emphasizing the importance of early diagnosis, appropriate staging, and personalized treatment approaches to improve patient outcomes and quality of life.

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

EP: 3.Immunotherapies for Extensive-Stage SCLC

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC

EP: 7.Payer and Patient Education Considerations for SCLC

EP: 8.Biomarker Discovery and Exploration for SCLC

Now Viewing

EP: 9.Key Takeaways on Recent Advances in SCLC

EP: 10.Therapies Beyond the Front Line for SCLC

EP: 11.Timing and Urgency Considerations in SCLC

We’ve discussed first-line therapies and a newly approved therapy tarlatamab.

Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about?
What are some of the therapies being researched for small cell lung cancer (SCLC) that you are excited about?

How do you see the management of SCLC evolving in the future?